Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions

Blood (2024) 144 (8): 867–872.

https://doi.org/10.1182/blood.2023023388

Published: 2024

Includes: Supplemental data

Journal Articles

Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study

Blood (2023) 142 (Supplement 1): 865.

https://doi.org/10.1182/blood-2023-172583

Published: 2023

Journal Articles

Iron homeostasis governs erythroid phenotype in polycythemia vera

Blood (2023) 141 (26): 3199–3214.

https://doi.org/10.1182/blood.2022016779

Published: 2023

Includes: Supplemental data

Journal Articles

Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CML

Blood (2022) 140 (Supplement 1): 192–194.

https://doi.org/10.1182/blood-2022-157244

Published: 2022

Journal Articles

Siremadlin, a Human Double Minute-2 (HDM2) Inhibitor, Added to Ruxolitinib after Suboptimal Response to Ruxolitinib Alone in Patients with Myelofibrosis: Results from Part 1 of the Phase 1/2 Adore Study

Blood (2022) 140 (Supplement 1): 590–593.

https://doi.org/10.1182/blood-2022-158501

Published: 2022

Journal Articles

A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses

Blood (2022) 140 (Supplement 1): 9717–9720.

https://doi.org/10.1182/blood-2022-167122

Published: 2022

Journal Articles

A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis

Blood (2021) 138 (Supplement 1): 139.

https://doi.org/10.1182/blood-2021-148682

Published: 2021

Journal Articles

Multicenter Prospective Evaluation of Diagnostic Potential of Flow Cytometric Aberrancies in Myelodysplastic Syndromes

Blood (2021) 138 (Supplement 1): 3995.

https://doi.org/10.1182/blood-2021-152298

Published: 2021

Journal Articles

Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis

Andrew Charles Perkins, MBBS,PhD, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Thomas Lehmann, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Andreas Reiter, MD, Vikas Gupta, MD FRCP, FRCPath, Claire Harrison, DM, FRCP, FRCPath, Jean-Jacques Kiladjian, MD PhD, Alessandro M. Vannucchi, MD, Marielle Wondergem, MD, Robert Pack, PhD, Monika Wroclawska, MD, Celine Wilke, MD, Angela Zhang, PhD, Florian H. Heidel, MD

Blood (2020) 136 (Supplement 1): 52–53.

https://doi.org/10.1182/blood-2020-140408

Published: 2020

Journal Articles

Molecular Response Patterns in Hydroxyurea (HU)-Resistant or Intolerant Polycythemia Vera (PV) during Treatment with Idasanutlin: Results of an Open-Label, Single-Arm Phase 2 Study

Francesco Passamonti, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Tarec Christoffer El-Galaly, Aaron T. Gerds, MDMS, Vikas Gupta, MD FRCP, FRCPath, Brian Higgins, Ling-Yuh Huw, PhD, Margherita Maffioli, MD, Ruben Mesa, MD, Jeanne M. Palmer, MD, Alessandro Rambaldi, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Alessandro M. Vannucchi, MD, Abdulraheem Yacoub, MD, John Mascarenhas, MD

Blood (2020) 136 (Supplement 1): 38–40.

https://doi.org/10.1182/blood-2020-136135

Published: 2020

Journal Articles

Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study

John Mascarenhas, MD, Brian Higgins, Doreen Anders, Kate Burbury, MD, Tarec Christoffer El-Galaly, Aaron T. Gerds, MDMS, Vikas Gupta, MD FRCP, FRCPath, Bruno Kovic, Margherita Maffioli, MD, Ruben Mesa, MD, Jeanne M. Palmer, MD, Francesco Passamonti, MD, Alessandro Rambaldi, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Alessandro M. Vannucchi, MD, Abdulraheem Yacoub, MD

Blood (2020) 136 (Supplement 1): 29–31.

https://doi.org/10.1182/blood-2020-135868

Published: 2020

Journal Articles

A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis

Kristen Pettit, MD, Aaron T. Gerds, MD MS, Abdulraheem Yacoub, MD, Justin M. Watts, MD, Maciej Tartaczuch, MD, Terrence J Bradley, MD, Jake Shortt, MBBS FRACP FRCPA PhD, William S. Stevenson, MBBS,PhD, Natasha Joan Curtin, MDFRACP,FRCPA, James M. Rossetti, DO, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Georges Natsoulis, PhD, Amber Jones, MA, Moshe Talpaz, MD, Jennifer Peppe, BS, David M Ross, MD PhD, Hugh Young Rienhoff, Jr., MD

Blood (2019) 134 (Supplement_1): 556.

https://doi.org/10.1182/blood-2019-123244

Published: 2019

Journal Articles

Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study

Blood (2019) 134 (Supplement_1): 4150.

https://doi.org/10.1182/blood-2019-127619

Published: 2019

Journal Articles

Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study

Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Amit Khot, MBBS, MD MRCP, FRCPath, FRACP, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Piers Blombery, MBBS, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, David Ritchie, MD PhD, Rodney J. Hicks, MB BS (Hons), MD FRACP, FAHMS, Besiat Birbirsa, B.N., Mathias Bressel, M.Sc, Juliana Di Iulio, PhD, David Alan Westerman, MBBS, FRCPA, FRACP, Stephen Lade, MBBS, FRCPA, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD FRACP, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 3999.

https://doi.org/10.1182/blood-2019-126396

Published: 2019

Journal Articles

Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Rodney J. Hicks, MB BS (Hons), MD FRACP, FAHMS, Besiat Birbirsa, B.N., Mathias Bressel, M.Sc, Juliana Di Iulio, PhD, David Alan Westerman, MBBS, FRCPA, FRACP, Stephen Lade, MBBS, FRCPA, Rishu Agarwal, Mark A. Dawson, PhD MBBS, Sarah-Jane Dawson, MD PhD, Rachel Koldej, David Ritchie, MD PhD, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 756.

https://doi.org/10.1182/blood-2019-126619

Published: 2019

Journal Articles

Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib

Chan Y. Cheah, Kate Burbury, Jane F. Apperley, Francoise Huguet, Vincenzo Pitini, Martine Gardembas, David M. Ross, Donna Forrest, Philippe Genet, Philippe Rousselot, Nigel Patton, Graeme Smith, Cynthia E. Dunbar, Sawa Ito, Ricardo C. T. Aguiar, Olatoyosi Odenike, Alla Gimelfarb, Nicholas C. P. Cross, John F. Seymour

Blood (2014) 123 (23): 3574–3577.

https://doi.org/10.1182/blood-2014-02-555607

Published: 2014

Journal Articles

Pulmonary Hypertension (PHT) and Pleural Effusion During Dasatinib Therapy For CML Frequently Lead To Drug Withdrawal

Maciek Tatarczuch, John F Seymour, MBBS, PhD, FRACP, Louise Creati, Elchanan H. Januszewicz, MBBS, Kate Burbury, MBBS, FRACP, FRCPA, DPhil

Blood (2013) 122 (21): 1504.

https://doi.org/10.1182/blood.V122.21.1504.1504

Published: 2013

Journal Articles

Lack Of Benefit From Surveillance PET-CT In Transformed Indolent Lymphoma (TrIL) In Complete Metabolic Remission (CMR) Following Therapy

Chan Y Cheah, MBBS, FRACP, FRCPA, Michael J. Dickinson, MBBS, FRACP, FRCPA, Anupkumar George, MBBS FRACP FRCPA, Michael S Hofman, MBBS FRACP FAANMS, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, David Ritchie, MBBS, FRACP, FRCPA, PhD, H Miles Prince, MB, BS, FRACP, FRCPA, MRACMA, MD, Kirsten Herbert, MD, BSci(Med), FRACP, PhD, Max Wolf, MBBS, FRACP, FRCPA, Elchanan H. Januszewicz, MBBS FRACP FRCPA, Dennis A Carney, MBBS FRACP FRCPA, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Constantine S Tam, MBBS, FRACP, FRCPA, MD, John F. Seymour, MBBS, FRACP, PhD

Blood (2013) 122 (21): 1796.

https://doi.org/10.1182/blood.V122.21.1796.1796

Published: 2013

Journal Articles

Incorporating High-Dose IV Methotrexate Into Initial Therapy Results In Lower Rates Of Central Nervous System (CNS) Relapse In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Chan Y Cheah, MBBS, FRACP, FRCPA, Kirsten Herbert, MD, BSci(Med), FRACP, PhD, Kacey O'Rourke, MBBS FRACP FRCPA, Glen Kennedy, MBBS FRACP FRCPA, Anupkumar George, MBBS FRACP FRCPA, Pasquale Fedele, MBBS, Shuh Ying Tan, MBBS, Stephen Opat, MBBS(Hons) FRACP FRCPA, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Max Wolf, MBBS, FRACP, FRCPA, Elchanan H. Januszewicz, MBBS FRACP FRCPA, Michael J. Dickinson, MBBS, FRACP, FRCPA, David A Westerman, MBBS, FRACP, FRCPA, H. Miles Prince, MBBS, FRACP, FRCPA, MD, Dennis A Carney, MBBS FRACP FRCPA, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Constantine S. Tam, MBBS, FRACP, FRCPA, MD, John F Seymour, MBBS, PhD, FRACP

Blood (2013) 122 (21): 4353.

https://doi.org/10.1182/blood.V122.21.4353.4353

Published: 2013

Journal Articles

BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis

Animesh Pardanani, MBBS, PhD, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, FRACP, PhD, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Srdan Verstovsek, MD, PhD, Hagop M. Kantarjian, MD, Kebede Begna, MD, Hiroyuki Yoshitsugu, PhD, Toni Ann Gestone, PhD, Penny Phillips, PhD, Guan Xing, PhD, Gerson Peltz, MD, MPH, Matthew V Lorenzi, PhD, Leila Alland, MD, Adrian Woolfson, BM BCh, PhD, Ayalew Tefferi, MD

Blood (2013) 122 (21): 664.

https://doi.org/10.1182/blood.V122.21.664.664

Published: 2013

NARROW

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions

Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study

Iron homeostasis governs erythroid phenotype in polycythemia vera

Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CML

Siremadlin, a Human Double Minute-2 (HDM2) Inhibitor, Added to Ruxolitinib after Suboptimal Response to Ruxolitinib Alone in Patients with Myelofibrosis: Results from Part 1 of the Phase 1/2 Adore Study

A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses

A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis

Multicenter Prospective Evaluation of Diagnostic Potential of Flow Cytometric Aberrancies in Myelodysplastic Syndromes

Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis

Molecular Response Patterns in Hydroxyurea (HU)-Resistant or Intolerant Polycythemia Vera (PV) during Treatment with Idasanutlin: Results of an Open-Label, Single-Arm Phase 2 Study

Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study

A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis

Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study

Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study

Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib

Pulmonary Hypertension (PHT) and Pleural Effusion During Dasatinib Therapy For CML Frequently Lead To Drug Withdrawal

Lack Of Benefit From Surveillance PET-CT In Transformed Indolent Lymphoma (TrIL) In Complete Metabolic Remission (CMR) Following Therapy

Incorporating High-Dose IV Methotrexate Into Initial Therapy Results In Lower Rates Of Central Nervous System (CNS) Relapse In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only